about
Radiation therapy for hepatocellular carcinomaA phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.In vivo bioluminescent imaging of irradiated orthotopic pancreatic cancer xenografts in nonobese diabetic-severe combined immunodeficient mice: a novel method for targeting and assaying efficacy of ionizing radiation.Pancreatic adenocarcinomaAmerican Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.Role of radiotherapy in the management of desmoid tumors.Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus.Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines.Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer CellsNCCN clinical practice guidelines in oncology: hepatobiliary cancersCaveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer.Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapyRadiotherapy for unresectable hepatic malignancies.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the PancreasQuality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.External-beam radiotherapy for localized extrahepatic cholangiocarcinoma.The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancerInitial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer.Opportunities and challenges in the era of molecularly targeted agents and radiation therapyPreclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
P50
Q28248864-1AF8F530-9E7C-4A82-9045-AC20FB58EA24Q33400984-E21C7611-7F09-43F3-9623-456F7B7E8773Q33408075-EF0EE406-A910-42F5-90E8-69D8190892EFQ33721749-1C631D2A-DAE2-4852-BDB6-B14A0A8E66D0Q33829414-EB064E18-353E-4DFC-AB47-97A20AAC724EQ33920915-A702B5EF-5DB1-4DC5-993F-EC061EC0B298Q34140498-9A29C2F9-317E-419D-8FB9-D8CD8686923DQ34325479-847F5780-EE74-4028-9FC5-FFFA2265D4A6Q34621324-A3A0604F-B855-454B-828D-28BC68C15BAEQ34845036-AACBC64C-09E5-4578-9568-5975A7FAA23EQ34845074-7EA54223-005F-455A-AB45-0AD025887B3FQ35182588-61380B91-B485-4504-9D60-7E948B4E6682Q35703937-8B38359E-C878-4474-84EE-0B895B1A33B3Q35727558-A6CCC379-B9C2-4135-8B8D-EB5399EE8364Q35776229-6D5BE11F-561A-4FDF-8285-07FA9A007096Q35947011-0006F816-5913-4496-AC92-59A6175836B9Q36059005-5873709F-1323-431D-A923-93D98A8C58A0Q36267549-BDD9C974-3463-43E0-9919-B151D588A440Q36376264-7F2A1EB5-2FDB-414C-8508-91D3CD35AF75Q36378003-BFC63F6F-8681-4566-A856-801B70A77E15Q36574645-70C06E47-7FF2-49D0-87D4-27C751B1F0C0Q36608448-F40CADAF-EF75-4EF5-A429-304AB9430ACBQ36626522-9072632E-9117-4F06-8991-735B29E1BAE9Q36778558-B9F3A972-6E1D-4AAF-84D5-163F4BA850CDQ36914411-82DC6BBB-F45A-4CA6-9ECD-08D4627C0B39Q36970534-3BCA2380-825F-4657-BC96-E014D322EBE1Q37021645-81D50DB1-13A4-4CAB-B82A-18723B8CA68BQ37036847-5FB1E313-0DFA-49F8-9194-40216EBA06DBQ37069689-8C7AB2BD-0CE5-4404-A09C-589FB5729851Q37072691-9EC60B35-740D-46C4-906B-EE713EB95749
P50
description
onderzoeker
@nl
name
Edgar Ben-Josef
@ast
Edgar Ben-Josef
@en
Edgar Ben-Josef
@es
Edgar Ben-Josef
@nl
Edgar Ben-Josef
@sl
type
label
Edgar Ben-Josef
@ast
Edgar Ben-Josef
@en
Edgar Ben-Josef
@es
Edgar Ben-Josef
@nl
Edgar Ben-Josef
@sl
prefLabel
Edgar Ben-Josef
@ast
Edgar Ben-Josef
@en
Edgar Ben-Josef
@es
Edgar Ben-Josef
@nl
Edgar Ben-Josef
@sl